We deliver you hope and ability to escape of hepatitis C and leave this life experience behind you.

*
Bien qu’il n’existe pas à ce jour de vaccin contre le virus de l’hépatite C (VHC), cette maladie peut être prise en charge et traitée grâce à des antiviraux. En plus des actions de santé publique pour la prévention, la Recherche et les laboratoires s’activent afin d’enrayer une épidémie qui cause environ « 2600 décès par an » en France. Et l’annonce récente de la recommandation de l’AMM (Autorisation de mise sur le marché) du Sovaldi® (Sofosbuvir) par l’Agence européenne du médicament n’est pas passée inaperçue.
But price cuts on the drugs are not exclusive to government bodies, according to Bloomberg News . Gilead Sciences will discount Harvoni and Sovaldi by an average of 46 percent. The discounts should make treatment more affordable and should affect policy change in the United States, to widen the scope of hepatitis C cases to which the new medications should be prescribed.
Date: April 16, 2016 Source: European Association for the Study of the Liver Summary: A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a 'short-duration' of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated study demonstrated that the combination of sofosbuvir and ledipasvir for only six weeks is sufficient to treat patients with acute HCV. Share:
Depending on the treatment history, cirrhosis status, and economic regions, the ICERs ranged from US$8,950 to US$89,470 per QALY gain when comparing sofosbuvir/ledipasvir to SOC (Table 2 ). By the WHO guideline of 3 times GDP per capita, sofosbuvir/ledipasvir was cost-effective in cirrhotic patients in Northeastern-, Central- and Western-China, and cost-effective in treatment-experienced patients in Eastern-China.
Author Topic: Daklinza Sofosbuvir Side Effects (Read 4048 times)
Treatment of recurrent Hepatitis C with sofosbuvir and simeprevir in post transplant patients in an academic liver center
Hepcinat Sovaldi Sofosbuvir
Sovaldi (sofosbuvir) används för behandling av kronisk hepatit C av genotyp 1-6 och ingår sedan tidigare i högkostnadsskyddet med begränsning. Sovaldi kvarstår i högkostnadsskyddet med oförändrad subvention efter den 1 januari 2017.
inktec.by/forum/sublimatsionnye/691-post...8-sofosbuvir-hiv-hcv
Results of Base-Case Analysis: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. Results of Sensitivity Analysis: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment.
Sofosbuvir is a nucleotide analogue inhibitor of the HCV NS5B protein, which plays an essential role in HCV replication. Sofosbuvir is a direct-acting agent, meaning that it interferes directly with the HCV life cycle by suppressing viral replication. Sofosbuvir is intended to become a cornerstone of interferon-free, all-oral treatment regimens for HCV that achieve higher cure rates more rapidly and with fewer side effects than current therapeutic options. Sofosbuvir is an investigational product and its safety and efficacy have not yet been established. – See more at: www.gilead.com/news/press-releases/2013/...sthash.iGipLk32.dpuf
Even in terms of price, Harvoni has a slight edge over Sovaldi. For a 12-week treatment Harvoni costs $94,500; however, as many patients only need the treatment for eight weeks, the price comes down to $63,000, making it much cheaper than a course with Sovaldi or other competitor drugs.